Search Results 651-660 of 12850 for Birth Control Evolution

  1. Publications - Todd A. Kellogg, M.D. - Mayo Clinic

    Evolution of NAFLD and Its Management. Nutr Clin Pract. 2020 Feb; 35 (1):72-84 Epub 2019 Dec 16. View PubMed; Hickson LJ, Langhi Prata LGP, Bobart SA, Evans ...

  2. Gastroenterology and Hepatology - Clinical trials

    Imperforate Anus, also known as anal atresia, is a rare birth defect. Unable to pass stool through the gastrointestinal tract, this condition can result in ...

  3. Gastroenterology and Hepatology - Clinical trials

    Imperforate Anus, also known as anal atresia, is a rare birth defect. Unable to pass stool through the gastrointestinal tract, this condition can result in ...

  4. Prenatal care: Third trimester visits - Mayo Clinic

    How will I know when I'm in labor? What's the best way to manage any pain? Should I make a birth plan? Talk to your care team about all the questions you have.

  5. Gastroenterology and Hepatology - Clinical trials

    Imperforate Anus, also known as anal atresia, is a rare birth defect. Unable to pass stool through the gastrointestinal tract, this condition can result in ...

  6. Mayo Clinic Q and A: Countdown to control anxiety

    Recent research shows mindfulness meditation may be as effective at reducing anxiety as medication for some people.

  7. Gastroenterology and Hepatology - Clinical trials

    Imperforate Anus, also known as anal atresia, is a rare birth defect. Unable to pass stool through the gastrointestinal tract, this condition can result in ...

  8. A Study to Assess the Effects of the Minnesota Medical Technologies Anal Insert Device in Fecal Incontinence - Mayo Clinic

    If applicable, Patient agrees to use acceptable birth control (surgical sterilization, abstinence, approved hormonal contraceptives such as birth control pills ...

  9. A Study to Evaluate Diabetes Management Using Quality of Life, Burden of Treatment, Social Integration and Avoidance of Future Events - Mayo Clinic

    Can QBSAfe be implemented in a clinical practice setting and improve quality of life, reduce treatment burden and hypoglycemia among older, complex patients ...

  10. A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia - Mayo Clinic

    Patients must use effective birth control throughout study until 1 year after rituximab treatment; female patients must not be pregnant or breast-feeding.